Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1b/2 Study Assessing the Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

NCT04888312 is registered in ClinicalTrials.gov with Alligator Bioscience AB as lead sponsor.

NCT NCT04888312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04888312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1b/2 Study Assessing the Safety and Efficacy of Mitazalimab in Combination With Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Lead sponsor
Alligator Bioscience AB
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 17, 2021
Completion date
June 30, 2026
Enrollment
94 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic ductal adenocarcinoma